Thieme E-Books & E-Journals -
Back
Horm Metab Res 2009; 41(12): 905-909
DOI: 10.1055/s-0029-1234042
Humans, Clinical

© Georg Thieme Verlag KG Stuttgart · New York

Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes

J. E. Foley1 , S. Sreenan2
  • 1Clinical Research & Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
  • 2Department of Endocrinology, Royal College of Surgeons in Ireland, Connolly Hospital, Dublin, Ireland